Retro Biosciences

CompanyUnited States

Retro Biosciences develops 3 assets, the furthest in phase 1 (RTR242 in Alzheimer's disease). Mostly cell therapy and small molecule acting on autophagy; based in the United States.

3
Assets
Furthest stage: Phase 1; 0
Trials: 3
Signals

Pipeline

RTR242
Oral small molecule that boosts autophagic flux to restart autophagy
Phase 1, Small molecule, Autophagy, Alzheimer's disease
RTR888
iPSC-derived microglial progenitors to renew the brain's immune cells
Preclinical, Cell therapy
RTR890
Rejuvenated iPSC-derived haematopoietic stem cells for transplantation
Preclinical, Cell therapy, blood disorders

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

Evidence behind the mechanisms1
People24
Signals3
Similar companies6

Papers

AI Driven Longevity Economics: Extending Dal Maso's Longevity Capitalism by the No-New-Actor Method, Chained Through the Research Horizon Gap and the Molecular Zero-Day to ALRP, and Stress-Tested Against the 2026 AI Bubble
Zenodo (CERN European Organization for Nuclear Research), 1 Jan 2026
The Best Case Already Failed: Why Longevity Governance Is the Hardest Case in the Comparative Record, and Why the Post-War Order That Might Have Governed It Is Dismantling Itself in Real Time
Zenodo (CERN European Organization for Nuclear Research), 1 Jan 2026
THE DEBT THAT DOES NOT WAIT: Why Longevity's Race to the Bottom Outpaces AI's Own, and Why Three Named Actors Now Hold Both Ends of the Pipe
1 Jan 2026
NO NEW ACTOR TO NAME: Erman and Furendal's Market and Epistemic Authority, the Frontier AI Labs Now Funding Longevity Research, and Why the Dubai Longevity Authority Is Where the Question Stopped Being Speculative
1 Jan 2026